HCW Biologics Says Preliminary Human Data For The First Two Dose Cohorts From Its Dose-escalating Phase 1 Trial Of HCW9302 For Alopecia Areata Shows Clinical Response After Single Dose Administration

HCW Biologics, Inc.

HCW Biologics, Inc.

HCWB

0.00
  • Potentially best-in-class IL-2 based treatment for autoimmune diseases by expanding and activating regulatory T cells
  • Readout for dose-escalating clinical study for first two dose cohorts
  • All participants in second dose cohort at the dose level of 3 micrograms/kg body weight showed positive clinical response after single dose administration
  • Well tolerated, with no dose-limiting toxicities or significant known IL-2-treatment-related adverse effects, including no reported incidence of capillary leak, cytokine release syndrome, or increase in blood eosinophil counts
  • HCW Biologics projects to establish the Recommended Phase 2 Dose by year end 2026
This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.